QOP
NKTR icon

Quinn Opportunity Partners’s Nektar Therapeutics NKTR Stock Holding History

Quinn Opportunity Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.9M Buy
179,247
+93,379
+109% +$5.32M 0.67% 40
2025
Q4 		$3.63M Sell
85,868
-24,000
-22% -$1.34M 0.15% 128
2025
Q3 		$6.25M Buy
+109,868
New +$3.64M 0.44% 66

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Quinn Opportunity Partners's NKTR Position: Q1 2026 in Review

Quinn Opportunity Partners increased its Nektar Therapeutics (NKTR) stake by 109% in Q1 2026, buying an estimated $5.32M and bringing the position to 179,247 shares worth $12.9M. The position accounts for 0.67% of the portfolio, ranked #40.

Quinn Opportunity Partners first reported a position in NKTR in Q3 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Quinn Opportunity Partners held 179,247 shares of Nektar Therapeutics worth $12.9M as of Q1 2026.
  • Quinn Opportunity Partners bought 93,379 Nektar Therapeutics shares in Q1 2026, an estimated $5.32M.
  • Nektar Therapeutics made up 0.67% of Quinn Opportunity Partners's portfolio in Q1 2026, its #40 holding.
  • Quinn Opportunity Partners first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Quinn Opportunity Partners's 13F filing for Q1 2026, filed 15 May 2026.